Formulary Decisions

Indication

For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Upadacitinib offers an additional treatment choice in the therapeutic class of janus ki...

For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Upadacitinib offers an additional treatment choice in the therapeutic class of janus kinase inhibitors.